Photo from wikipedia
The use of tenofovir alafenamide (TAF) has been associated with increased cholesterol and body weight. Real‐life data on the metabolic effects of switching from a TAF‐based triple regimen to a… Click to show full abstract
The use of tenofovir alafenamide (TAF) has been associated with increased cholesterol and body weight. Real‐life data on the metabolic effects of switching from a TAF‐based triple regimen to a dolutegravir (DTG)‐based two‐drug regimen (2‐DR) are scarce.
Keywords:
parameters switching;
change metabolic;
switching triple;
metabolic parameters;
triple regimens;
tenofovir alafenamide
Journal Title: HIV Medicine
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: HIV Medicine
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!